Skip to main content
. 2017 Sep;38(9):1672–1680. doi: 10.3174/ajnr.A5148

Fig 3.

Fig 3.

Axial T2-weighted and contrast-enhanced T1-weighted images showing imaging signs suggestive of natalizumab-associated PML (A and B) with follow-up imaging post-withdrawal of medication suggestive of PML–immune reconstitution inflammatory syndrome. This patient demonstrates the most frequent pattern of PML IRIS, with patchy contrast enhancement in the border of the lesion (arrows). Reproduced from Wattjes et al39 with permission from BMJ Publishing Group Ltd.